Manufacturer ImmunoGen, Inc., has announced that Elahere™ (mirvetuximab soravtansine-gynx) has been approved as a folate receptor alpha (FRα)-directed antibody and microtubule 4 Drug News – Volume 9, Issue 12 inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

• Elahere is an intravenous infusion administered once every 3 weeks (21-day cycle). Dosage is based on each patient’s ideal body weight.
• ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.
• It is not known if this medicine is safe and effective in children. • Read more… https://www.drugs.com/pro/elahere-injection.html#s-43685